Related Experiment Video
Updated: May 22, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
941
Post-COVID-19 Inflammatory Arthritis Treated With Upadacitinib: A Case Report
1Rheumatology, Ami Ben-Artzi, MD Inc., Scripps Hospital, San Diego, USA.
Cureus
|March 13, 2025
Abstract:
Two patients who developed inflammatory arthritis following COVID-19 infection are presented, characterized by arthralgias, arthritis, and elevated markers of inflammation (C-reactive protein). Both patients had clinically meaningful responses to treatment with upadacitinib, a Janus Kinase inhibitor (JAKi). This case report highlights the efficacy and safety of upadacitinib in the treatment of post-COVID-19 inflammatory arthritis.
Keywords:
auto-immune molecular mimicryinflammatory arthritisjak inhibitormolecular mimicry in covid-19poly-arthralgiapolyarticular arthritispost covid-19 syndromepost-covid-19upadacitinibviral arthritisMore Related Videos
Related Concept Videos
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107

